Pediatrics & Therapeutics
Open Access

Abstract

Evaluate the Efficacy and Safety of Lucinactant in Preventing Bronchopulmonary Dysplasia (BPD) in Premature Infants

Alaa Abuzaid*, Shadi Noaman Garrada

Aim: To evaluate the efficacy and safety of Lucinactant in preventing Bronchopulmonary Dysplasia (BPD) in premature infants. Methods: The article included eight studies on the use of Lucinactant in preventing BPD in premature infants. Three of the four studies were published clinical trials and four were registered protocols without yet-published results. The article included 1281 participants from 8 clinical trials, of whom 137 received nCPAP only, 1016 received Lucinactant and 128 received other therapies. Results: The article found that the evidence on the efficacy of Lucinactant in preventing BPD is mixed. Some studies have shown that Lucinactant is effective in reducing the incidence of BPD, while others have not. More research is needed to confirm the efficacy of Lucinactant in preventing BPD in premature infants. The article also found that Lucinactant may be associated with a lower mortality rate than other surfactant therapies. However, more data is needed to confirm this finding. Conclusion: The article concludes that Lucinactant is a potential new therapy for preventing BPD in premature infants. However, more research is needed to confirm its efficacy and safety.

Published Date: 2024-12-05; Received Date: 2024-11-05